Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.5270
-0.0230 (-4.18%)
At close: Apr 1, 2025, 4:00 PM
0.5461
+0.0191 (3.62%)
After-hours: Apr 1, 2025, 4:46 PM EDT
Oncolytics Biotech Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Oncolytics Biotech stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 659.01% from the current stock price of 0.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Oncolytics Biotech stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +469.26% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +848.77% | Mar 10, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +848.77% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +848.77% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +848.77% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
from 444.92M
Revenue Next Year
n/a
EPS This Year
-0.40
from -0.41
EPS Next Year
-0.42
from -0.40
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.3M | 49.7M | 153.3M | ||
| Avg | 1.2M | 12.0M | 62.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -98.6% | 4,001.4% | 1,182.1% | ||
| Avg | -99.7% | 886.3% | 420.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.38 | -0.13 | ||
| Avg | -0.40 | -0.42 | -0.34 | ||
| Low | -0.46 | -0.48 | -0.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.